未登录

M

Malika Danner

department of radiation oncology

H指数:8

被引数:363

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Persistent bothersome urinary frequency following stereotactic body radiation therapy for clinically localized prostate cancer: rationale for prophylactic β3-agonist in men with elevated baseline international prostate symptom scores

立体定向体部放射治疗临床局限性前列腺癌后持续烦人的尿频：基线国际前列腺症状评分升高男性中预防性β3-激动剂使用的依据

Frontiers in Oncology

IF3.3

2026-01-160

OAAI

Utilization of patient-reported outcomes to assess adherence to relugolix when combined with stereotactic body radiation therapy for intermediate to high-risk prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-300

OAAI

Maintenance of patient-reported health-related quality of life post neoadjuvant relugolix prior to the initiation of prostate radiation therapy

在开始前列腺放射治疗之前，在新辅助relugolix后维持患者报告的健康相关生活质量

FRONTIERS IN ONCOLOGY

IF3.3

2025-01-170

OAAI

Late radiation-related lymphopenia after prostate stereotactic body radiation therapy plus or minus supplemental pelvic irradiation

FRONTIERS IN ONCOLOGY

IF3.3

2024-11-210

OAAI

Safety and early efficacy of involved-field SBRT for nodal oligo-recurrent prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2024-10-170

OAAI

The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue

FRONTIERS IN ONCOLOGY

IF3.3

2024-08-121

OAAI

Impact of neoadjuvant relugolix on patient-reported sexual function and bother

FRONTIERS IN ONCOLOGY

IF3.3

2024-04-112

OAAI

Prognostic utility of biopsy-based PTEN and ERG status on biochemical progression and overall survival after SBRT for localized prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2024-03-223

OAAI

Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes

FRONTIERS IN ONCOLOGY

IF3.3

2023-11-233

OAAI

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2023-10-174

OAAI

Robotic Stereotactic APBI for Early-Stage Breast Cancer: 2-year Outcomes of a Prospective Multi-Institutional Trial

CANCER RESEARCH

IF16.6

2023-03-010

PRE

Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-12-231

OAAI

Patient-Reported Financial Burden Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-03-256

OAAI

Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer

JOURNAL OF SEXUAL MEDICINE

IF3.3

2022-03-171

PRE

Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-01-190

OAAI

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy

FRONTIERS IN ONCOLOGY

IF3.3

2021-09-171

OAAI

Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2021-02-256

OAAI

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer

FRONTIERS IN ONCOLOGY

IF3.3

2020-10-292

OAAI

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15)

FRONTIERS IN ONCOLOGY

IF3.3

2020-07-039

OAAI

Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP)

FRONTIERS IN ONCOLOGY

IF3.3

2020-05-0517

OAAI